≡ Risteys R6

Methods Changelog GitHub Contact & Feedback

Tumor necrosis factor alpha inhibitors

PheWeb

No definition available.

Endpoint definition

↥
FinnGen phenotype data
diagram bullet diagram downward connector

Filter registries KELA purch., KELA reimb.

Medicine purchases: ATC L04AB
Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

diagram bullet diagram downward connector

Include endpoints

Check conditions None

Apply sex-specific rule None

diagram downward connector RX_L04AB

Extra metadata

First used in FinnGen datafreeze DF4

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 2467 1530 937
Unadjusted prevalence (%) 0.95 1.04 0.83
Mean age at first event (years) 46.57 46.38 46.89

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.02 1.49 [0.63, 3.50] 3.6e-1 27
15 years 0.01 1.49 [0.63, 3.50] 3.6e-1 27
5 years 0.00 2.00 [0.83, 4.81] 1.2e-1 12
1 year - - - -

Correlations

↥

Index endpoint: RX_L04AB – Tumor necrosis factor alpha inhibitors
GWS hits:

Survival analyses between endpoints

↥

Plot

before Tumor necrosis factor alpha inhibitors
after Tumor necrosis factor alpha inhibitors

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Tumor necrosis factor alpha inhibitors

↥